Actively Recruiting
Characteristics and Outcomes of ICU Patients With Severe Acute COPD Exacerbations Observational Study of Clinical Features, Treatments, and Survival Factors
Led by Alexis FERRE · Updated on 2026-10-27
2000
Participants Needed
4
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a prospective observational study to understand the characteristics and outcomes of patients admitted to intensive care units ICU with severe acute exacerbations of chronic obstructive pulmonary disease COPD. The study aims to describe the epidemiological, clinical, and biological features of these patients and assess the treatments they receive. It also evaluates short, mid, and long-term prognosis, focusing on mortality rates up to one year and factors linked to survival. The study collects pseudonymized data from medical records of patients admitted to ICUs, step-up units, or respiratory care units due to severe COPD exacerbations. The research follows strict legal and ethical guidelines and does not involve any experimental treatments, as it is purely observational. Patients receive usual care, and data on their clinical status and treatments are gathered for analysis. Participants involvement includes the review of medical files and data collection without additional interventions. Researchers measure key outcomes like ICU mortality at discharge, mortality at 30 and 90 days, and patient characteristics at ICU admission. The study runs from October 2022 to April 2028, with primary data collection concluding by October 2027. Participation requires non-opposition consent, and patient confidentiality is maintained throughout the study.
CONDITIONS
Brief Title
Characteristics and Outcomes of Patients Admitted to ICU for a Severe Acute Exacerbation of COPD.
Research Team
A
Alexis Ferré, M.D.
L
Laure Morisset
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here